Resources
BioPharma Dive Online April 4, 2022 Read the Full Article >> The large quantity of digitized healthcare data in the U.S., combined with advancements in data collection and processing technologies, present an enormous opportunity to shift dramatically how post-marketing safety studies can and should be conducted. The Traditional Approach Post-marketing safety studies are a[…]
Read the Press Release>> BOSTON, March 31, 2022 /PRNewswire/ — OM1, a leading technology enabled real-world data and artificial intelligence (AI) company with a focus on delivering insights into multiple chronic diseases, today announces the launch of its Mental Health and Neuroscience Specialty Area led by physician and entrepreneur, Dr. Carl D. Marci. The division includes new data on psychiatric[…]
Pharmaceutical Executive Online Published: March 15, 2022 Read the Full Article >> If you were asked which health care conditions rank as the highest in both unmet need and in cost, which would you choose? Would it be cancer or heart disease? While those conditions certainly place in both categories, mental health outranks them in[…]
BioMed Central Online Published: 14 February 2022 Read the Full Manuscript >> Background Many second-generation antipsychotics (SGAs) are associated with weight gain and cardiometabolic effects. Antipsychotic-associated weight gain is linked to treatment interruptions, potentially increasing risk of relapse and hospitalization. This retrospective study assessed clinically significant weight gain (CSWG), treatment interruptions, and development of cardiometabolic[…]
OM1’s Dr. Richard Gliklich presents on leveraging the AAO-HFN Reg-ent Registry for research at the FDA-MDEpiNet conference “Cochlear Implant Innovation, Research and Advancement (CIRCA). View Agenda >>
